Arch Biopartners Inc. (ACHFF)
OTCMKTS · Delayed Price · Currency is USD
0.5800
-0.0249 (-4.12%)
At close: Jul 27, 2026
Arch Biopartners Revenue
Arch Biopartners had revenue of 158.08K CAD in the twelve months ending March 31, 2026. In the fiscal year ending September 30, 2025, Arch Biopartners had annual revenue of 275.94K, down -87.00%.
Revenue (ttm)
158.08K CAD
Revenue Growth
-87.00%
P/S Ratio
347.92
Revenue / Employee
n/a
Employees
n/a
Market Cap
39.40M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 275.94K | -1.85M | -87.00% |
| Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 37.65M |
| Sangamo Therapeutics | 34.56M |
| Nuo Therapeutics | 4.13M |
| ZIVO Bioscience | 209.03K |
| Provectus Biopharmaceuticals | 57.48K |
Arch Biopartners News
- 11 days ago - Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program - GlobeNewsWire
- 20 days ago - Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors - GlobeNewsWire
- 7 weeks ago - Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans - GlobeNewsWire
- 2 months ago - Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial - GlobeNewsWire
- 3 months ago - Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI - GlobeNewsWire
- 4 months ago - Arch Biopartners Closes Non-Brokered Private Placement - GlobeNewsWire
- 4 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 4 months ago - Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial - GlobeNewsWire